Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $486,871,000 | $502,672,000 | $447,187,000 | $361,361,000 |
| % Growth | -3.1% | 12.4% | 23.8% | – |
| Cost of Goods Sold | $147,950,000 | $127,126,000 | $110,062,000 | $93,511,000 |
| Gross Profit | $338,921,000 | $375,546,000 | $337,125,000 | $267,850,000 |
| % Margin | 69.6% | 74.7% | 75.4% | 74.1% |
| R&D Expenses | $149,866,000 | $112,377,000 | $95,344,000 | $75,879,000 |
| G&A Expenses | $125,671,000 | $73,370,000 | $68,806,000 | $62,623,000 |
| SG&A Expenses | $125,671,000 | $97,389,000 | $86,643,000 | $74,119,000 |
| Sales & Mktg Exp. | $0 | $24,019,000 | $17,837,000 | $11,496,000 |
| Other Operating Expenses | $3,637,000 | $2,677,000 | $2,844,000 | $2,938,000 |
| Operating Expenses | $279,174,000 | $212,443,000 | $184,831,000 | $152,936,000 |
| Operating Income | $59,747,000 | $163,103,000 | $152,294,000 | $114,914,000 |
| % Margin | 12.3% | 32.4% | 34.1% | 31.8% |
| Other Income/Exp. Net | -$419,000 | $631,000 | -$8,762,000 | -$9,889,000 |
| Pre-Tax Income | $59,328,000 | $163,734,000 | $143,532,000 | $105,025,000 |
| Tax Expense | $9,163,000 | $35,694,000 | $30,619,000 | $24,340,000 |
| Net Income | $50,047,000 | $127,977,000 | $112,723,000 | $80,519,000 |
| % Margin | 10.3% | 25.5% | 25.2% | 22.3% |
| EPS | 106.55 | 266.61 | 230.85 | 162.19 |
| % Growth | -60% | 15.5% | 42.3% | – |
| EPS Diluted | 106.41 | 266.6 | 230.79 | 162.16 |
| Weighted Avg Shares Out | 469,704 | 480,016 | 488,300 | 496,459 |
| Weighted Avg Shares Out Dil | 470,322 | 480,088 | 488,353 | 496,527 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,774,000 | $4,027,000 | $2,478,000 | $2,710,000 |
| Interest Expense | $5,318,000 | $229,000 | $913,000 | $874,000 |
| Depreciation & Amortization | $26,894,000 | $18,140,000 | $17,451,000 | $17,721,000 |
| EBITDA | $91,540,000 | $178,435,000 | $167,496,000 | $128,536,000 |
| % Margin | 18.8% | 35.5% | 37.5% | 35.6% |